Hence, it is still possible that high-level HER2 overexpression due to gene amplification does predict recurrence after a primary DCIS but the tumor biology explaining why recurrences after a HER2+ DCIS more often are of the in situ type remains to be explored. This evidence concerns the gene ERBB2 and neoplasm.